Literature DB >> 20228390

Who should pay for assisted reproductive techniques? Answers from patients, professionals and the general public in Germany.

O Rauprich1, E Berns, J Vollmann.   

Abstract

BACKGROUND: Financing ART is variously regulated in the different countries of Europe. In Germany, coverage of assisted reproduction by statutory health insurances was restricted to 50% in 2004. We conducted a national survey among patients, professionals (physicians and other academics in IVF centres, psychosocial counsellors, medical ethicists, social lawyers, health politicians) and the general public in Germany regarding their opinions on financing ART.
METHODS: Standard questionnaire techniques (paper and pencil interviewing, computer-aided web interviewing, computer-aided telephone interviewing) were used.
RESULTS: The vast majority of all groups supported public coverage of ART. Co-payments by patients were considered appropriate by about one-third of the patients, two-third of the physicians and three quarters of all other groups. According to the respondents, the amount of co-payment should cover 15-25% of the costs, considerably less than what patients actually have to pay (50%). Support for public coverage was strongly correlated with the views (i) of infertility as a disease, (ii) that there is a need for assisted reproduction for infertile couples and (iii) that every human should have the opportunity to have children. The respondents had varying opinions on whether to increase medical insurance premiums in order to cover ART. Reducing services in other areas of health care in favour of reproductive medicine was supported only by the group of reproductive physicians. Financial incentives for oocyte sharing were rejected by most groups as was a money-back guarantee for unsuccessful treatments.
CONCLUSIONS: Experts and the general public in Germany accept moderate co-payments for ART. No clear pattern of opinion emerged regarding the question of how public co-funding should be financed.

Entities:  

Mesh:

Year:  2010        PMID: 20228390     DOI: 10.1093/humrep/deq056

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Male fertility and reduction in semen parameters: a single tertiary-care center experience.

Authors:  D Milardi; G Grande; D Sacchini; A L Astorri; G Pompa; A Giampietro; L De Marinis; A Pontecorvi; A G Spagnolo; R Marana
Journal:  Int J Endocrinol       Date:  2012-01-26       Impact factor: 3.257

2.  Disinvestment policy and the public funding of assisted reproductive technologies: outcomes of deliberative engagements with three key stakeholder groups.

Authors:  Katherine Hodgetts; Janet E Hiller; Jackie M Street; Drew Carter; Annette J Braunack-Mayer; Amber M Watt; John R Moss; Adam G Elshaug
Journal:  BMC Health Serv Res       Date:  2014-05-05       Impact factor: 2.655

3.  Infertility in public health: the case of Norway.

Authors:  J Sundby
Journal:  Facts Views Vis Obgyn       Date:  2010

Review 4.  Low-cost in vitro fertilization: current insights.

Authors:  Pek Joo Teoh; Abha Maheshwari
Journal:  Int J Womens Health       Date:  2014-08-21

5.  Decision analysis about the cost-effectiveness of different in vitro fertilization-embryo transfer protocol under considering governments, hospitals, and patient.

Authors:  Wei Pan; Haiting Tu; Lei Jin; Cheng Hu; Yuehan Li; Renjie Wang; Weiming Huang; ShuJie Liao
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.

Authors:  Weiguang Xue; Adam Lloyd; Edel Falla; Claudia Roeder; Rudiger Papsch; Klaus Bühler
Journal:  Int J Womens Health       Date:  2019-05-13

7.  Is the public supportive and willing to pay for a national assistive reproductive therapies programme? Results from a multicountry survey.

Authors:  Chris Skedgel; Eleanor Ralphs; Elaine Finn; Jennifer A Whitty; Marie Markert; Carl Samuelsen
Journal:  BMJ Open       Date:  2021-03-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.